464 Followers on Owler
Iovance is a California-based biotechnology company that develops autologous T cell-based immunotherapies for the treatment of patients with solid tumours and blood cancers...
Read moreIovance is a California-based biotechnology company that develops autologous T cell-based immunotherapies for the treatment of patients with solid tumours and blood cancers...
Read more
2007
PublicIndependent CompanyNASDAQIOVA
News
Mar 08, 2023
Owler
Iovance Biotherapeutics, Inc.: Iovance's employee count changed from 319 in Dec 2021 to 503 in Dec 2022
Mar 01, 2023
Zacks
Iovance: Iovance (IOVA) Q4 Earnings In Line With Estimates, Revenues Nil
Feb 28, 2023
Markets Insider
Iovance: Iovance Biotherapeutics GAAP EPS of -$0.64 in-line (NASDAQ:IOVA)
Feb 28, 2023
GlobeNewswire
Press Release: Iovance : Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
Feb 26, 2023
Pharamceutical Technology
Iovance: Cellular Immunotherapy for Non-Small Cell Lung Cancer by Iovance Biotherapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
Feb 07, 2023
Global Legal Chronicle
Iovance: Iovance Biotherapeutics' $200 Million Acquisition of Proleukin
Jan 27, 2023
Seeking Alpha
Iovance: Iovance gains as Piper sees approval for melanoma therapy this year
Jan 23, 2023
Benzinga
Iovance: Iovance Biotherapeutics Acquires Clinigen's IL-2 Product For Upfront 166.7M
Dec 09, 2022
Seeking Alpha
Iovance: Iovance downgraded at Goldman Sachs citing concerns on lead asset
Dec 05, 2022
Seeking Alpha
Iovance: Iovance adds 21% on $65M insider purchase
Looking for similar companies to Iovance?
Iovance News
Iovance Press Releases
Iovance Headquarters
Iovance Summary
ABOUT
Overview
Iovance is a California-based biotechnology company that develops autologous T cell-based immunotherapies for the treatment of patients with solid tumours and blood cancers. Iovance was founded in 2007. Iovance's headquarters is located in San Carlos...CEO
Iovance's Interim President & CEO, Frederick G. Vogt, currently has an approval rating of 85%. Iovance's primary competitors are Idera, Nektar, Checkmate Pharmaceuticals and 12 more.Website
iovance.comCompetitors
View 15 Iovance competitors here.Acquisitions
There have been no acquisitions found related to IovanceInvestments
Recent investment data cannot be found related to IovanceFrequently Asked Questions about Iovance
When was Iovance founded?
Iovance was founded in 2007Who is Iovance's CEO?
Iovance's CEO is Frederick G. VogtHow much revenue does Iovance generate?
Iovance generates $2.4M in revenueHow much funding does Iovance have?
Iovance has historically raised $1.2B in funding
Where is Iovance's headquarters?
Iovance's headquarters is in San Carlos California, USAHow many employees does Iovance have?
Iovance has 500 employeesWhat sector does Iovance operate in?
Iovance is in BiotechnologyWho are Iovance's competitors?
Iovance's top competitors are Idera, Nektar, Checkmate Pharmaceuticals